+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Viral Vectors & Plasmid DNA Manufacturing Market Size, Share & Trends Analysis Report by Vector (Lentivirus, Retrovirus), by Workflow, by Application, by End Use, by Disease, and Segment Forecasts, 2020 - 2027

  • ID: 4751750
  • Report
  • February 2020
  • Region: Global
  • 250 pages
  • Grand View Research

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • Addgene, Inc.
  • Batavia Biosciences B.V.
  • BlueBird Bio
  • Genezen
  • Novasep Holding S.A.S
  • VGXI, Inc.
  • MORE
The global viral vectors & plasmid DNA manufacturing market size is expected to reach USD 1.1 billion by 2027, exhibiting a 14.52% CAGR, during the forecast period according to this report. Currently, more than 700 cell and gene therapies are in clinical trials and vectors are used in nearly 70% of these therapies. As a result, demand for vectors has exceeded the supply rate. Thus, an increase in the number of advanced therapy-based discovery programs initiated by biotechnology and pharmaceutical companies is expected to drive investments in the market.

Current production methods for viral vectors are considered tedious, as they are only applicable for scale-out but not for scale-up. Development of a proprietary CAP-GT technology-based cell suspension system by CEVEC Pharmaceuticals GmbH has effectively addressed the challenge of scaling-up by allowing easy handling and improved efficiency of cells.

Considering growing opportunities in vector production, the Original Equipment Manufacturers (OEMs) are making focused efforts to gain a competitive advantage in the market. For example, the introduction of ready-to-run factory-in-a-box to accelerate the production of virus-based therapeutics by GE healthcare, as a solution to simplify and advance the manufacturing process.

Further key findings from the report suggest:
  • With high usage, attributed to its ability of high titer production and capability to induce strong humoral and T cell responses in various research applications, adenovirus held the leading viral vectors and plasmid DNA manufacturing market share in terms of revenue, in 2019
  • Lentivirus vector is anticipated to register the fastest CAGR over the forecast period. This can be attributed to constant growth in the lentivirus-based gene therapy pipeline program
  • Downstream processing held the dominant revenue share in 2019, owing to the fact that this process involves purification steps that account for the majority of the overall manufacturing cost. Employment of expensive equipment and requirement of trained personnel for product recovery has further driven revenue in the segment
  • Antisense and RNAi therapy production is estimated as the key application of vector manufacturing, resulting in the dominance of this segment over other applications
  • The high adoption rate of viruses for aptamers and oligonucleotide development in comparison to other applications has driven revenue in antisense and RNAi therapy segment
  • High usage of vectors for therapeutic production have contributed to the large revenue share of pharmaceutical and biopharmaceutical companies. The number of biotech companies employing vector for therapies production is anticipated to multiply over the forecast period
  • Presence of a substantial number of advanced therapy products in the pipeline targeting various cancer forms has accelerated revenue share of the cancer segment over the years
  • Given the high number of biotech entities in parts of U.S., such as in California and Massachusetts, North America has maintained its dominance in terms of revenue. In addition, the active participation of regulatory bodies in improving the regulatory scenario for the market launch of advanced therapies has facilitated the high usage of vectors in U.S.
  • Merck, Cobra Biologics, Novasep, and uniQure N.V., are some key participants that are geared towards capitalizing the untapped opportunities in the market

Please note: This product will be delivered within 48 business hours after receipt of order.
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Addgene, Inc.
  • Batavia Biosciences B.V.
  • BlueBird Bio
  • Genezen
  • Novasep Holding S.A.S
  • VGXI, Inc.
  • MORE
Chapter 1 Executive Summary

1.1 Market Snapshot

Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Formulation & Validation

Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.1.1 Market driver analysis
3.1.1.1 Robust pipeline for gene therapies and viral vector vaccines
3.1.1.2 Technological advancements in manufacturing vectors
3.1.1.3 Highly competitive market and various strategies undertaken by market entities
3.1.2 Market restraint analysis
3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy
3.1.3 Challenge analysis
3.1.3.1 Production capacity challenges
3.1.3.1 Manufacturing challenges pertaining to large-scale production of vectors
3.1.4 Opportunity analysis
3.1.4.1 Facility expansion for cell and gene therapies
3.2 Viral Vector Production: Stepwise Challenges & Solutions
3.2.1 Plasmid Production: Challenges & Solutions
3.2.2 Host Cell Production & Banking Needs
3.2.3 Viral Vector Production, F&F: Challenges & Solutions
3.2.4 Viral Vector Production, Analytics: Challenges & Solutions
3.3 Penetration & Growth Prospect Mapping for Vector Type, 2019
3.4 Penetration & Growth Prospect Mapping for Prominent Industry Players, 2019
3.5 Manufacturer’s Landscape
3.6 Viral Vector & Plasmid DNA Manufacturing Market-SWOT Analysis, By Factor (Political & Legal, Economic, and Technological)
3.7 Industry Analysis - Porter’s

Chapter 4 Viral Vector Production Capacity Mapping Analysis
4.1 CMOs Capacity for Viral Vector Manufacturing
4.2 In-house Manufacturers Capacity for Viral Vector Manufacturing
4.3 Cleanroom Suites Facilities: Leading Viral Vector Manufacturers
4.4 Prominent Players: Location Mapping & existing Capacities
4.5 AAV and LV vector candidate developing organizations
4.6 CMO Mammalian Cell Culture Capacity of Key Players in Viral Vector/Gene/Cell Therapy Space: Key Statistics
4.7 Mammalian cell lines: Capacity & Investments
4.7.1 Small Scale Companies: Mammalian Cell Culture Capacities
4.7.2 Medium scale companies: Mammalian cell culture capacities
4.7.3 Large scale companies: Mammalian cell culture capacities
4.8 List of Companies with Portfolio Comprising Vector-based Therapeutic Candidates
4.9 List of Vector Manufacturers

Chapter 5 Viral Vector Production: Costs
5.1 Cost Models
5.1.1 Campaign model
5.1.2 Day rate model
5.1.3 Hybrid model

Chapter 6 Viral Vector Production & Yield Analysis
6.1 Production Yields: Biomarin, Spark Therapeutics & Solid Biosciences
6.2 Various Modes of Vector Production to increase & achieve Target Doses
6.2.1 Adenoviral vectors
6.2.2 γ- retroviral (MLV - murineleukemia virus) vectors
6.2.3 Lentiviral vectors
6.2.4 AAV vectors
6.2.5 rAAV vectors
6.2.5.1 rAAV Production : Challenges & Solutions
6.3 Total vector quantity produced per day and yield volume using different cell culture systems
6.4 Measures undertaken to optimize manufacturing of viral vectors for cell and gene therapy
6.5 Analysis of large- and small-scale production of viral vectors based on batch size
6.5.1 Small-scale/laboratory-scale cell culture systems
6.5.2 Large-scale cell culture systems
6.6 Common Practices for Small-Scale (10-50L) Adenovirus Vector Manufacturing

Chapter 7 Viral Vector Manufacturing: Process Economic Considerations & Challenges
7.1 Technological Advances in Manufacturing
7.1.1 STable Producer Cell Lines
7.1.2 Transient production
7.1.3 Lentiviral vector production process
7.1.3.1 Developments in LentiVector platform
7.2 CoGs Analysis of the Baseline Process
7.2.1 Raw Material
7.2.2 Labor costs
7.2.3 Process costs
7.3 Regulatory Expectations
7.4 Approaches for Viral Vector Supply Gene Therapy
7.4.1 Gene Therapy Manufacturing Facilities: Trends & Types
7.4.2 Gene Therapy Road Map: Key External Trends

Chapter 8 Viral Vector Manufacturing Market: Strategic Alliances
8.1 Is The Time Right To Invest In Gene Therapy Sector?
8.2 Strategic Approaches for Market Scale-Up
8.3 Partnership Models
8.3.1 Acquisition
8.3.2 Minority interest (ownership)
8.3.3 Joint venture
8.3.4 Alliance
8.3.5 Franchise
8.4 Collaborations in Viral Vector Manufacturing Market
8.4.1 Breakthrough Growth: Lonza, Oxford BioMedica & Others

Chapter 9 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Vector Type Estimates & Trend Analysis
9.1 Viral Vector & Plasmid DNA Manufacturing Market: Vector Type Movement Analysis
9.2 Adenovirus
9.2.1 Global adenovirus market, 2016 - 2027 (USD Million)
9.3 Retrovirus
9.3.1 Global retrovirus market, 2016 - 2027 (USD Million)
9.4 Plasmid DNA
9.4.1 Global plasmid DNA market, 2016 - 2027 (USD Million)
9.5 AAV
9.5.1 Global AAV market, 2016 - 2027 (USD Million)
9.6 Lentivirus
9.6.1 Global lentivirus market, 2016 - 2027 (USD Million)
9.7 Other Vectors
9.7.1 Global other vectors market, 2016 - 2027 (USD Million)

Chapter 10 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Workflow Estimates & Trend Analysis
10.1 Viral Vector & Plasmid DNA Manufacturing Market: Workflow Movement Analysis
10.2 Upstream Manufacturing
10.2.1 Global upstream manufacturing market, 2016 - 2027 (USD Million)
10.2.2 Vector amplification & expansion
10.2.2.1 Global vector amplification & expansion market, 2016 - 2027 (USD Million)
10.2.3 Vector recovery/harvesting
10.2.3.1 Global vector recovery/harvesting market, 2016 - 2027 (USD Million)
10.3 Downstream Manufacturing
10.3.1 Global downstream manufacturing market, 2016 - 2027 (USD Million)
10.3.2 Purification
10.3.2.1 Global purification market, 2016 - 2027 (USD Million)
10.3.3 Fill Finish
10.3.3.1 Global fill finish market, 2016 - 2027 (USD Million)

Chapter 11 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Application Estimates & Trend Analysis
11.1 Viral Vector & Plasmid DNA Manufacturing Market: Application Movement Analysis
11.2 Antisense & RNAi Therapy
11.2.1 Market for antisense, & RNAi therapy, 2016 - 2027 (USD Million)
11.3 Cell Therapy
11.3.1 Market for cell therapy, 2016 - 2027 (USD Million)
11.4 Gene Therapy
11.4.1 Market for gene therapy, 2016 - 2027 (USD Million)
11.5 Vaccinology
11.5.1 Market for vaccinology, 2016 - 2027 (USD Million)

Chapter 12 Viral Vector & Plasmid DNA Manufacturing Market Categorization: End-use Estimates & Trend Analysis
12.1 Viral Vector & Plasmid DNA Manufacturing Market: End-use Movement Analysis
12.2 Pharmaceutical and Biopharmaceutical Companies
12.2.1 Market for pharmaceutical and biopharmaceutical companies, 2016 - 2027 (USD Million)
12.3 Research Institutes
12.3.1 Market for research institutes, 2016 - 2027 (USD Million)

Chapter 13 Viral Vector & Plasmid DNA Manufacturing Market Categorization: Disease Estimates & Trend Analysis
13.1 Viral Vector & Plasmid DNA Manufacturing Market: Disease Movement Analysis
13.2 Cancer
13.2.1 Market for cancer, 2016 - 2027 (USD Million)
13.3 Genetic Disorders
13.3.1 Market for genetic disorders, 2016 - 2027 (USD Million)
13.4 Infectious Diseases
13.4.1 Market for infectious diseases, 2016 - 2027 (USD Million)
13.5 Others
13.5.1 Market for other diseases, 2016 - 2027 (USD Million)

Chapter 14 Market Categorization: Regional Estimates & Trend Analysis, by Product
14.1 Viral Vector & Plasmid DNA Manufacturing Market Share By Regional, 2019 & 2027
14.2 North America
14.2.1 North America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.2.2 U.S.
14.2.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.2.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.2.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.2.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.2.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.2.3 Canada
14.2.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.2.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.2.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.2.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.2.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.3 Europe
14.3.1 Europe viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.3.2 Germany
14.3.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.3.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.3.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.3.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.3.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.3.3 U.K.
14.3.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.3.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.3.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.3.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.3.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.4 Asia Pacific
14.4.1 Asia Pacific viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.4.2 Japan
14.4.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.4.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.4.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.4.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.4.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.4.3 China
14.4.3.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.4.3.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.4.3.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.4.3.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.4.3.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.5 Latin America
14.5.1 Latin America viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.5.2 Brazil
14.5.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.5.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.5.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.5.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.5.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)
14.6 MEA
14.6.1 MEA viral vector & plasmid DNA manufacturing market, 2016 - 2027 (USD Million)
14.6.2 South Africa
14.6.2.1 Viral vector & plasmid DNA manufacturing market, by vector type, 2016 - 2027 (USD Million)
14.6.2.2 Viral vector & plasmid DNA manufacturing market, by workflow, 2016 - 2027 (USD Million)
14.6.2.3 Viral vector & plasmid DNA manufacturing market, by application, 2016 - 2027 (USD Million)
14.6.2.4 Viral vector & plasmid DNA manufacturing market, by end-use, 2016 - 2027 (USD Million)
14.6.2.5 Viral vector & plasmid DNA manufacturing market, by disease, 2016 - 2027 (USD Million)

Chapter 15 Competitive Landscape
15.1 Strategy Framework
15.2 Market Participation Categorization
15.3 Company Profiles: Contract Manufacturing Organizations (CMOs)
15.3.1 Merck KGaA
15.3.1.1 Company overview
15.3.1.1.1 Sigma-Aldrich Co. LLC
15.3.1.2 Financial performance
15.3.1.3 Product benchmarking
15.3.1.4 SWOT analysis
15.3.1.5 Operational capacity
15.3.1.6 Strategic initiatives
15.3.2 Lonza
15.3.2.1 Company overview
15.3.2.2 Financial performance
15.3.2.3 Product benchmarking
15.3.2.4 SWOT analysis
15.3.2.5 Operational capacity
15.3.2.6 Strategic initiatives
15.3.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
15.3.3.1 Company overview
15.3.3.2 Financial performance
15.3.3.3 Product benchmarking
15.3.3.4 SWOT analysis
15.3.3.5 Operational capacity
15.3.3.6 Strategic initiatives
15.3.4 Cobra Biologics Ltd.
15.3.4.1 Company overview
15.3.4.2 Financial performance
15.3.4.3 Product benchmarking
15.3.4.4 SWOT analysis
15.3.4.5 Operational capacity
15.3.4.6 Strategic initiatives
15.3.5 Brammer Bio
15.3.5.1 Company overview
15.3.5.2 Financial performance
15.3.5.3 Product benchmarking
15.3.5.4 SWOT analysis
15.3.5.5 Operational capacity
15.3.5.6 Strategic initiatives
15.3.6 Waisman Biomanufacturing
15.3.6.1 Company overview
15.3.6.2 Financial performance
15.3.6.3 Product benchmarking
15.3.6.4 SWOT analysis
15.3.6.5 Operational capacity
15.3.6.6 Strategic initiatives
15.3.7 Genezen
15.3.7.1 Company overview
15.3.7.2 Product benchmarking
15.3.7.3 SWOT analysis
15.3.7.4 Operational capacity
15.3.7.5 Strategic initiatives
15.3.8 YPOSKESI
15.3.8.1 Company overview
15.3.8.2 Financial performance
15.3.8.3 Product benchmarking
15.3.8.4 SWOT analysis
15.3.8.5 Operational capacity
15.3.8.6 Strategic initiatives
15.3.9 Advanced BioScience Laboratories, Inc. (ABL, Inc.)
15.3.9.1 Company overview
15.3.9.2 Financial performance
15.3.9.3 Product benchmarking
15.3.9.4 SWOT analysis
15.3.9.5 Operational capacity
15.3.9.6 Strategic initiatives
15.3.10 Novasep Holding S.A.S
15.3.10.1 Company overview
15.3.10.2 Product benchmarking
15.3.10.3 SWOT analysis
15.3.10.4 Operational capacity
15.3.10.5 Strategic initiatives
15.3.11 ATVIO Biotech Ltd
15.3.11.1 Company overview
15.3.11.2 Financial performance
15.3.11.3 Product benchmarking
15.3.11.4 SWOT analysis
15.3.11.5 Operational capacity
15.3.11.6 Strategic initiatives
15.3.12 Vigene Biosciences, Inc.
15.3.12.1 Company overview
15.3.12.2 Financial performance
15.3.12.3 Product benchmarking
15.3.12.4 SWOT analysis
15.3.12.5 Operational capacity
15.3.12.6 Strategic initiatives
15.3.13 General Electric Company (GE Healthcare)
15.3.13.1 Company overview
15.3.13.2 Financial performance
15.3.13.3 Product benchmarking
15.3.13.4 SWOT analysis
15.3.13.5 Operational capacity
15.3.13.6 Strategic initiatives
15.3.14 CEVEC Pharmaceuticals GmbH
15.3.14.1 Company overview
15.3.14.2 Financial performance
15.3.14.3 Product benchmarking
15.3.14.4 SWOT analysis
15.3.14.5 Operational capacity
15.3.14.6 Strategic initiatives
15.3.15 Batavia Biosciences B.V.
15.3.15.1 Company overview
15.3.15.2 Financial performance
15.3.15.3 Product benchmarking
15.3.15.4 SWOT analysis
15.3.15.5 Operational capacity
15.3.15.6 Strategic initiatives
15.3.16 Biovian Oy
15.3.16.1 Company overview
15.3.16.2 Financial performance
15.3.16.3 Product benchmarking
15.3.16.4 SWOT analysis
15.3.16.5 Operational capacity
15.3.16.6 Strategic initiatives
15.3.17 Wuxi AppTec Co., Ltd.
15.3.17.1 Company overview
15.3.17.2 Financial performance
15.3.17.3 Product benchmarking
15.3.17.4 SWOT analysis
15.3.17.5 Operational capacity
15.3.17.6 Strategic initiatives
15.3.18 VGXI, Inc.
15.3.18.1 Company overview
15.3.18.2 Financial performance
15.3.18.3 Product benchmarking
15.3.18.4 SWOT analysis
15.3.18.5 Operational capacity
15.3.18.6 Strategic initiatives
15.3.19 Paragon Bioservices, Inc
15.3.19.1 Company overview
15.3.19.2 Financial performance
15.3.19.3 Product benchmarking
15.3.19.4 SWOT analysis
15.3.19.5 Operational capacity
15.3.19.6 Strategic initiatives
15.3.20 Miltenyi Biotec GmbH
15.3.20.1 Company overview
15.3.20.2 Lentigen Technology, Inc.
15.3.20.3 Financial performance
15.3.20.4 Product benchmarking
15.3.20.5 SWOT analysis
15.3.20.6 Operational capacity
15.3.20.7 Strategic initiatives
15.3.21 SIRION Biotech GmbH
15.3.21.1 Company overview
15.3.21.2 Financial performance
15.3.21.3 Product benchmarking
15.3.21.4 SWOT analysis
15.3.21.5 Operational capacity
15.3.21.6 Strategic initiatives
15.3.22 Virovek Incorporation
15.3.22.1 Company overview
15.3.22.2 Financial performance
15.3.22.3 Product benchmarking
15.3.22.4 SWOT analysis
15.3.22.5 Operational capacity
15.3.22.6 Strategic initiatives
15.3.23 BioNTech IMFS GmbH
15.3.23.1 Company overview
15.3.23.2 Financial performance
15.3.23.3 Product benchmarking
15.3.23.4 SWOT analysis
15.3.23.5 Operational capacity
15.3.24 VIVEbiotech S.L.
15.3.24.1 Company overview
15.3.24.2 Financial performance
15.3.24.3 Product benchmarking
15.3.24.4 SWOT analysis
15.3.24.5 Operational capacity
15.3.24.6 Strategic initiatives
15.3.25 Creative Biogene
15.3.25.1 Company overview
15.3.25.2 Product benchmarking
15.3.25.3 SWOT analysis
15.3.26 Vibalogics GmbH
15.3.26.1 Company overview
15.3.26.2 Product benchmarking
15.3.26.3 SWOT analysis
15.3.26.4 Operational capacity
15.3.26.5 Strategic initiatives
15.4 Company Profiles: In-house Manufacturers
15.4.1 Cell and Gene Therapy Catapult
15.4.1.1 Company overview
15.4.1.2 Product benchmarking
15.4.1.3 SWOT analysis
15.4.1.4 Operational capacity
15.4.1.5 Strategic initiatives
15.4.2 BlueBird Bio
15.4.2.1 Company overview
15.4.2.2 Financial performance
15.4.2.3 Product benchmarking
15.4.2.4 SWOT analysis
15.4.2.5 Operational capacity
15.4.2.6 Strategic initiatives
15.4.3 Addgene, Inc.
15.4.3.1 Company overview
15.4.3.2 Financial performance
15.4.3.3 Product benchmarking
15.4.3.4 SWOT analysis
15.4.3.5 Operational capacity
15.4.3.6 Strategic initiatives
15.4.4 Aldevron, L.L.C.
15.4.4.1 Company overview
15.4.4.2 Financial performance
15.4.4.3 Product benchmarking
15.4.4.4 SWOT analysis
15.4.4.5 Operational capacity
15.4.4.6 Strategic initiatives
15.4.5 Audentes Therapeutics
15.4.5.1 Company overview
15.4.5.2 Financial performance
15.4.5.3 Product benchmarking
15.4.5.4 SWOT analysis
15.4.5.5 Operational capacity
15.4.5.6 Strategic initiatives
15.4.6 BioMarin Pharmaceutical
15.4.6.1 Company overview
15.4.6.2 Financial performance
15.4.6.3 Product benchmarking
15.4.6.4 SWOT analysis
15.4.6.5 Operational capacity
15.4.6.6 Strategic initiatives
Note: Product cover images may vary from those shown
  • Merck KGaA
  • Sigma-Aldrich Co. LLC
  • Lonza
  • FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
  • Cobra Biologics Ltd.
  • Brammer Bio
  • Waisman Biomanufacturing
  • Genezen
  • YPOSKESI
  • Advanced BioScience Laboratories, Inc. (ABL, Inc.)
  • Novasep Holding S.A.S
  • ATVIO Biotech Ltd
  • Vigene Biosciences, Inc.
  • General Electric Company (GE Healthcare)
  • CEVEC Pharmaceuticals GmbH
  • Batavia Biosciences B.V.
  • Biovian Oy
  • Wuxi AppTec Co., Ltd.
  • VGXI, Inc.
  • Paragon Bioservices, Inc
  • Miltenyi Biotec GmbH
  • SIRION Biotech GmbH
  • Virovek Incorporation
  • BioNTech IMFS GmbH
  • VIVEbiotech S.L.
  • Creative Biogene
  • Vibalogics GmbH
  • Cell and Gene Therapy Catapult
  • BlueBird Bio
  • Addgene, Inc.
  • Aldevron, L.L.C.
  • Audentes Therapeutics
  • BioMarin Pharmaceutical
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll